Intelligence · Clinical Pipeline
Neurology & CNS · Phase II
Neurology & CNS programs at Phase II — ClinicalTrials.gov pipeline intelligence.
- Programs
- 230
Quick answer
Neurology & CNS Phase II programs: NovaPharmaNews indexes 230 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- BRIGHT MINDS BIOSCIENCES 13 programs
- United Therapeutics Europe 12 programs
- Chinese Academy of 11 programs
- Teva Pharma 11 programs
- Jazz Pharmaceuticals Ireland 10 programs
- Acadia Pharmaceuticals 9 programs
- HOFFMANN-LA ROCHE 9 programs
- George Institute for 8 programs
- SUPERNUS PHARMACEUTICALS 8 programs
- Cognition Therapeutics 7 programs
- Takeda 7 programs
- Anaxis Pharma 6 programs
-
TPM XR
SUPERNUS PHARMACEUTICALS, INC.
Epilepsy
1 trial -
Talampanel
Teva Pharma GmbH
Epilepsy
1 trial -
TolDec
The George Institute
Multiple sclerosis
1 trial -
Trontinemab, Placebo Trontinemab, Flortaucipir F18
Hoffmann-La Roche
Alzheimer's disease
1 trial -
UB-311
United Therapeutics Europe Ltd
Alzheimer's Disease
3 trials -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Remitting Multiple Sclerosis
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
multiple sclerosis
1 trial -
VX-765
Vertex Pharmaceuticals (Australia) Pty.
Partial Epilepsy
1 trial -
VX-765 Part A
Vertex Pharmaceuticals (Australia) Pty.
Epilepsy
1 trial -
VY7523
Voyager Therapeutics
Alzheimer's Disease (AD)
1 trial -
Venlafaxine
BRIGHT MINDS BIOSCIENCES INC.
Depression
1 trial -
Vitamin D3
United Therapeutics Europe Ltd
Parkinson Disease
1 trial -
Wei Li Bai capsules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Alzheimer Disease
1 trial -
XPF-010, XPF-008, XEN1101 placebo
Xenon Pharmaceuticals
Adult focal (partial onset) epilepsy
1 trial -
YTB323, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, TOCILIZUMAB
Novartis Pharmaceuticals
Non-active Progressive Multiple Sclerosis (PMS)
1 trial -
[123I] 5-IA
United Therapeutics Europe Ltd
Parkinson Disease
1 trial -
[123I]B-CIT
United Therapeutics Europe Ltd
Parkinson Disease
1 trial -
[123I]β-CIT
United Therapeutics Europe Ltd
Parkinson Disease
1 trial -
[18F]PI-2620
The George Institute
Down Syndrome., Alzheimer´s Disease.
1 trial -
[18F]PI-2620
The George Institute
Down Syndrome, Alzheimer disease
1 trial -
[18F]PI-2620
The George Institute
Progressive supranuclear palsy, Parkinson's disease
1 trial -
[90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor
Alphapharm Pty Ltd
Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary
1 trial -
armodafinil
Teva Pharma GmbH
Schizophrenia
2 trials -
ataluren
PTC THERAPEUTICS, INC.
Epilepsy
1 trial -
fetal nigral transplantation
Ultragenyx UK Limited
Parkinson Disease
1 trial -
florquinitau F18, JNJ-64042056, JNJ-64042056
Janssen-Cilag International N.V.
Preclinical Alzheimer’s Disease
1 trial -
glatiramer acetate 20 mg
Teva Pharma GmbH
Relapsing Remitting Multiple Sclerosis
1 trial -
glatiramer acetate 20 mg
Teva Pharma GmbH
Relapse-Remitting Multiple Sclerosis
1 trial -
glatiramer acetate with minocycline
Teva Pharma GmbH
Relapse Remitting Multiple Sclerosis
1 trial -
laquinimod 0.3
Teva Pharma GmbH
Relapsing Remitting Multiple Sclerosis
1 trial -
levodopa
United Therapeutics Europe Ltd
Parkinson Disease
1 trial -
methylprednisolone
Teva Pharma GmbH
Multiple Sclerosis (MS)
1 trial -
mutual support group
Hong Kong Baptist University
Schizophrenia
1 trial -
pallidotomy
Ultragenyx UK Limited
Parkinson Disease
1 trial -
pioglitazone
Takeda
Alzheimer Disease
1 trial -
sabirnetug
Acumen Pharmaceuticals
Alzheimer Disease
1 trial -
sarcosine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
1 trial -
sodium oxybate
Jazz Pharmaceuticals Ireland Limited
Parkinson Disease
1 trial
Frequently asked questions
How many neurology & cns Phase II programs exist?
230 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs